601. Preliminary Results of BÂRRX Ablation Trial in Patients with Non-Dysplastic Intestinal Metaplasia Versus Low Or High Grade Dysplasia
- Author
-
Sonya Reicher, Daniel C. Chung, Samuel W. French, Reza Khoshini, Viktor E. Eysselein, Mehrdad Vosoghi, and Franklin Tsai
- Subjects
medicine.medical_specialty ,business.industry ,Nausea ,medicine.medical_treatment ,Gastroenterology ,Lansoprazole ,Intestinal metaplasia ,medicine.disease ,Ablation ,medicine.anatomical_structure ,Tolerability ,Dysplasia ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Esophagus ,medicine.symptom ,business ,Odynophagia ,medicine.drug - Abstract
Preliminary Results of BÂRRX Ablation Trial in Patients with Non-Dysplastic Intestinal Metaplasia Versus Low Or High Grade Dysplasia Franklin Tsai, Mehrdad Vosoghi, Reza Khoshini, Sonya Reicher, David Chung, Samuel French, Viktor Eysselein Aims: Assess the response associated with BÂRRX ablation of Barrett’s esophagus (BE) in patients with no dysplasia (ND) vs low grade dysplasia (LGD) or high grade dysplasia (HGD), as well as short segment (SSBE, !3 cm) vs long segment (LSBE, O3 cm). Methods: Prospective trial in patients with BE confirmed by bx on prior EGD. Patients receive 2 ablations at 10 J/cm in the ND group or 12 J/cm in the LGD group during each treatment. Tolerability is recorded using a 7-day, 10-pt scale patient symptom diary. All patients receive lansoprazole 30 mg bid and have 3 & 12 mo follow-up EGD with 4-quadrant bx every 1 cm from original BE region. Any patients with all bx negative are deemed to have complete response (CR). Patients with intestinal metaplasia present on any bx or incomplete response (IR) return at 6 mo for repeat treatment. Patients with known HGD who are not surgical candidates are evaluated with EUS to rule out invasion. Those with HGD limited to the mucosa will undergo EMR if not already done, then return in 2 mo to proceed with the BÂRRX ablation at 12 J/cm. Results: 11 of 75 planned patients (5 male, mean age 57.6, 9 ND, 1 LGD, 1 HGD, 8 LSBE, mean length 5.7 cm, range 1 to 11 cm, 3 SSBE) have been treated. One patient refused follow-up EGD & dropped out of the study. 3-mo follow-up EGD is pending for 4 patients. Amongst the 6 patients (5 ND, 1 HGD, 4 LSBE) who have already returned for 3-mo follow-up EGD, all had complete healing with no evidence of BE on EGD, except 2 patients with !2 cm patches of residual BE. In the ND group, all 4 LSBE patients had IR while the one SSBE patient had CR. The patient with HGD & SSBE had CR after one treatment. The mean percentage of negative bx at 3 mo was 54% (range 20 to 88%) for LSBE versus 100% for SSBE, with a mean of 69.3% for all 6 patients. Amongst all 11 treated patients, the procedure was better tolerated by those with SSBE (mean 2/10 symptom score) vs LSBE (6.6/10). The most frequently reported symptoms were odynophagia & nausea. There were no strictures, perforations, or other serious complications. Conclusions: Preliminary data suggests that BÂRRX ablation is safe, well-tolerated, & effective at clearing SSBE (!3 cm). Our first patient with HGD had CR with ablation at 12 J/cm. Data are pending for patients with LGD. LSBE was most associated with IR, but given the high percentage of negative bx (54%), we expect significant rates of CR after these patients return for repeat ablation.
- Published
- 2006